GLP-1 Startup Kailera Leads Biotech IPO Revival With $625M Deal
Kailera Therapeutics’ $625M GLP-1 IPO anchors a Q2 2026 healthcare listing wave, with Hemab Therapeutics, Avalyn Pharma, and peers all jumping 52-89% from their offer prices.
Kailera Therapeutics’ $625M GLP-1 IPO anchors a Q2 2026 healthcare listing wave, with Hemab Therapeutics, Avalyn Pharma, and peers all jumping 52-89% from their offer prices.
Cerebras Systems targets a $40B valuation in its IPO, backed by a landmark OpenAI deal and AWS Bedrock integration that transformed its revenue base.
Bill Ackman’s Pershing Square raises $5B in a dual NYSE IPO but shares sink ~18% on debut as retail demand misses the original $25B target.